Abstract:
One or more embodiments of the present invention provide a novel composition for gene delivery are directed to a group of polysaccharide polymers, having one or more nucleic acid delivery side chains comprising cationic peptides. In some embodiments, these cationic peptides condense and physically bond to one or more nucleic acids to form a polysaccharide-nucleic acid complex that permits delivery to and transfection of the nucleic acid(s) into cells. In some embodiments, the polysaccharide polymers of the present invention may also have one or more zwitterionic side chains and/or reactive side chains.
Abstract:
A discretely tunable locally seeded laser device is provided. The discretely tunable locally seeded laser device comprises: a first tunable laser comprising first discrete output modes; and, a second tunable laser arranged to receive output from the first tunable laser, but otherwise optically isolated from the first tunable laser, the second tunable laser comprising second discrete output modes, such that one first discrete output mode can optically seed an aligned second discrete output mode in a given position of one or more of the first discrete output modes and the second discrete output modes, the aligned second discrete output mode comprising a dominant output.
Abstract:
A cathode boss structure for an aluminum electrolytic cell is disclosed. The cathode boss is arranged on the top surface of the cathode carbon block or on the top of the gap between two cathode carbon blocks. The distance between cathode bosses is 400 mm-900 mm. The length of the throughout elongate cathode boss is 100-250 mm longer than that of cathode carbon block, and two ends thereof are directly embedded into the paste around lateral portion. The length of the embedded and butted cathode boss is in a range of 3000-3200 mm, two ends thereof are fixed by binding carbon blocks respectively, and the binding carbon blocks are embedded into the paste around lateral portion. The cross-section of the cathode boss structure is in the shape of rectangle or isosceles trapezoid. The cathode boss structure is applicable to all types of current electrolytic cells. The strip boss is implanted into the top surface of the cathode of the electrolytic cell conveniently and quickly when the lateral portion of the common electrolytic cell is rammed, thereby forming a “choking effect”, reducing the flow rate of the aluminum liquid layer, decreasing energy dissipation from the aluminum liquid layer, therefore improving the production stability of the electrolytic cell and reducing energy consumption.
Abstract:
A device using the live welding method for aluminum electrolytic cell overhauling under series full current consists of short-circuit buses at the bottom of the cell (1), pillar buses (2), an anode bus (3), a balance bus (4), a inter-cell standby bus (5), a door-shaped pillar clamp (6), an arcuate clamp (7) of anode buses, a current conversion switch (8, a mechanical switching device (9) for the short-circuit port, a voltage sensor and wires thereof (10), a temperature sensor and wires thereof (11), a system (12) for data acquiring, displaying, analyzing and alarming, an A-side welding area (13), a B-side welding area (14) and compression-joint points (15) on pillar soft belts of overhauling cells; and the live welding method comprises the following steps: when welding is required to be performed in some zone, the currents of short-circuit buses at the bottom of the cell (1) and pillar buses (2) which influence the welding area most are cut off, the serial currents are shunted to other pillar buses (2), other buses at the bottom of the cell (1) and the inter-cell standby buses (5) such that the magnetic field intensity at the welding area can be lowered to the extent that welding can be performed so as to perform welding, and such a device and method can achieve live welding of aluminum electrolytic cells overhauling under series full current.
Abstract:
A method of estimating an injection power of seed light injected into an injection-seeded transmitter. A back face monitoring (BFM) response of the injection-seeded transmitter is determined, and data representative of the BFM response stored in a memory. During run-time, a controller of the injection-seeded transmitter, detects a temperature of the injection-seeded transmitter and an instantaneous BFM current. BFM response data is obtained from the memory based on the detected temperature, and the seed light injection power estimated based on the obtained data and the detected instantaneous BFM current.
Abstract:
The present invention is directed to a compound of Formula (I) wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).
Abstract:
The embodiments of the present invention disclose an event detection method and device. The method includes: predefining event-based detection rules with a predicative context-free grammar; generating by parsing the detection rules a parsing table of pushdown automaton which supports parallel parsing; receiving an event to be detected; and analyzing by a controller the event to be detected according to the parsing table, to obtain a detection result. The present invention is especially applicable to detection of network attack events. The embodiments of the present invention detect the attacks with a predicative context-free grammar on the basis of events, and ensure a close combination of a protocol parsing process and an attack detection process, as well as a close combination of multiple attack detection rules, thus decreasing unnecessary calculations. In addition, with an optimized parallel pushdown automaton, the embodiments of the present invention can efficiently analyze the predicative context-free grammar. Consequently, besides hierarchical processing capability and state description capability, the embodiments of the present invention deliver high efficiency.
Abstract:
The present invention is directed to a compound of Formula (I) wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).
Abstract:
One or more embodiments of the present invention provide a novel composition for gene delivery are directed to a group of polysaccharide polymers, having one or more nucleic acid delivery side chains comprising cationic peptides. In some embodiments, these cationic peptides condense and physically bond to one or more nucleic acids to form a polysaccharide-nucleic acid complex that permits delivery to and transfection of the nucleic acid(s) into cells. In some embodiments, the polysaccharide polymers of the present invention may also have one or more zwitterionic side chains and/or reactive side chains.